LinkedIn / Modulari-T Bioscience · Jul 2026
Company post promoted a podcast appearance by CEO Tanya E. Borsuk and reiterated Modulari-T's in vivo CAR-T / cell-therapy positioning and Montreal roots.
We teach your immune system to attack and cure cancer
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Montreal-based biotechnology company developing a proprietary 2nd-generation in vivo cell & gene therapy platform built around MARC and MoVe. Public sources describe it as a preclinical, partnership-oriented biotech focused on oncology, autoimmunity, and inflammation; no public GitHub, X, or engineering blog surfaced in the reviewed sources.
Primary product
MARC (Modular Actuation Receptor Complex) plus MoVe (Modular Vector) platform for in vivo cell and gene therapy
Founded
2021
Headquarters
Montreal, Quebec, Canada
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Cell and gene therapy / immunotherapy
Offices
Montreal, Quebec, Canada
7141 Rue Sherbrooke Ouest, Montreal, Quebec, Canada
1250 Rue Guy, Montreal, Quebec H3H 2T4, Canada
Business model
wholly-owned drug development
partnered assets / strategic collaborations
platform partnering / licensing
Funding
Stage
pre-seed
Total raised
$725K
Latest round
Merck Digital Sciences Studio cohort funding · Mar 2026
Latest amount
$100K
Merck Digital Sciences Studio cohort funding
Mar 2026 · Merck Global Health Innovation Fund / The Venture Collective / CQDM
Aug 2023
Apr 2023 · Y Combinator
Jan 2020
People & investors
Leadership
Chief Executive Officer
President & CSO
Co-founder & COO
Co-founder, VP of R&D
Co-Founder & CSO
Work & culture
Science-first, mission-driven startup culture; the company describes itself as a tight-knit 'Mod Squad' in Montreal and emphasizes original research, recruiting, lab buildout, and rapid biotech execution.
Compensation
A public Montreal job posting listed a Research Associate / Process Development role at $55K-$72K CAD per year on a fixed-term contract, suggesting early-career biotech compensation; no broader public comp bands were found.
Benefits
medical
vision
dental
transportation plan (carshare/bikeshare)
20 days vacation per year
Product & market
Pricing
No public product pricing; the public model appears to be platform partnering plus wholly-owned program development.
Differentiators
- —Developed both the receptor (MARC) and delivery vector (MoVe) from scratch
- —Positions itself as a complete 2nd-generation in vivo CGT system
- —MARC includes separate targeting and signaling with on/off control and bispecific options
- —MoVe is designed to reduce liver toxicity and improve selective in vivo targeting
- —Claims reduced exhaustion, stronger persistence, and lower toxic cytokine secretion than traditional CARs
- —Can target immune and non-immune cells and support multiple payload formats
Technology
MARC (Modular Actuation Receptor Complex)
MoVe (Modular Vector)
in vivo cell & gene therapy
AI protein design
de-targeted viral vectors
pH-sensitive / logic-gated receptor design
bispecific receptor engineering
targeted delivery to immune and non-immune cells
Customers
strategic biopharma partners
Competitors
Carisma Therapeutics
Verismo Therapeutics
4D Molecular Therapeutics
Capstan Therapeutics
Umoja Biopharma
Sana Biotechnology
Orna Therapeutics
Scale & contact
Estimated monthly visits
33
Latest news
Business Wire · Apr 2026
Modulari-T appointed Tanya E. Borsuk CEO and moved co-founder David Cotnoir-White into the President & CSO role, describing the company as entering a late-stage, partnership-driven phase.
LinkedIn / Modulari-T Bioscience · Mar 2026
Company post highlighted the MDSS selection, combined investment from Merck Global Health Innovation Fund and CQDM, and mentoring from Merck, TVC, and ecosystem partners.
Merck · Mar 2026
Modulari-T was selected for the MDSS cohort in Montreal and is slated to receive $100,000 USD total funding plus mentorship from Merck, TVC, and CQDM.
Jobs and careers at Modulari-T
0 jobs at Modulari-T
No open positions
Check back later for new openings